Sophie B. Willemse

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Meike H. van der Ree, J. Marleen de Vree, F. Stelma et al. · The Lancet · 2017 · 259 citations

Phase 1B, Hepatology, Hepatitis C +7

The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm – volume 2

Angelos Hatzakis, Vladimir Chulanov, Adrián Gadano et al. · Journal of Viral Hepatitis · 2015 · 124 citations · Full text

Viremic Population, Autoimmune Liver Disease, Viral Hepatitis +19

Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2

V A Saraswat, Suzanne Norris, Robert J. de Knegt et al. · Journal of Viral Hepatitis · 2015 · 93 citations · Full text

Strategies to manage hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infection disease burden – volume 2

Edward Gane, David Kershenobich, Carole Seguin‐Devaux et al. · Journal of Viral Hepatitis · 2015 · 53 citations · Full text

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101

F. Stelma, Meike H. van der Ree, Marjan J. Sinnige et al. · Hepatology · 2017 · 52 citations · Full text